Immune Tolerance Network
The Power of Collaboration
The Immune Tolerance Network (ITN) is a non-profit, government-funded consortium of over 80 researchers working together to establish new treatments for diseases of the immune system. The ITN is led by some of the world's foremost authorities on immune tolerance – physicians, basic and clinical researchers, and technology professionals from academia, government and industry.
UCSF is home to the ITN and our Diabetes Center Director Dr. Jeffrey Bluestone is also the Director of the ITN.
The ITN conducts clinical trials of specialized immune tolerance therapies in the following areas:
- The treatment of autoimmune diseases such as type 1 diabetes, multiple sclerosis, lupus and others;
- The prevention of organ transplant rejection in liver, kidney and islet transplantation;
- The prevention and treatment of allergies and asthma.
As well, each ITN clinical trial includes a coordinated set of laboratory studies of the genetic, cellular and immunological mechanisms behind the experimental treatment. These studies are designed to help find out how the body reacts to the treatment, and to find better ways of measuring immune tolerance in the immune system.
The ITN was founded in 1999 by the National Institute of Allergy and Infectious Diseases (NIAID) and receives support from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Juvenile Diabetes Research Foundation (JDRF).
ITN Clinical Trial Information